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Knuckle wireChronic total occlusions (CTOs) of coronary arteries represent a common and signiﬁcant challenge to inter-
ventional cardiology. Medical therapy is often regarded as an adequate long term strategy in the management
of these lesionswith surgical intervention for refractory symptoms. Extensive collateralisation is used as amarker
of distal coronary perfusion, further reinforcing non-invasive strategies. This together with relatively low
percutaneous success rates outside of specialised centres has meant that rates of percutaneous intervention
have remained low. Increasing evidence suggests that CTOs are not a benign entity. Further, symptom control
and quality of life improve signiﬁcantly with successful percutaneous revascularisation. Both factors have
reignited interest in percutaneous modalities. The Japanese have been pioneers in the ﬁeld of CTO intervention
although their success rates have been difﬁcult to replicate. New techniques and equipment developed in
North America offer an alternative to the Japanese approach. These techniques focus on time, radiation and
contrastminimisation. This reviewwill assess the histopathology of CTO and shifting paradigms inCTO treatment
strategies.
Crown Copyright © 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A chronic total occlusion (CTO) is usually deﬁned as a total obstruction
of a coronary artery of greater than three months duration. The duration
of occlusion has implications for the histopathological characteristics
and the success rates associated with intervention. It can occasionally be
determined from previous angiography. However, often a combination
of clinical history and angiographic features is required to support the
diagnosis.
Among patients diagnosed with coronary disease on angiography,
CTO’s are common, occurring in 20 to 30% of patients [1]. The presence
of a CTO often inﬂuences treatment recommendations and is the
strongest predictor of referral for coronary artery bypass surgery
(CABG) [2]. Revascularisation remains challenging irrespective of themo-
dality selected. For example, in the SYNTAX trial [3], percutaneous coro-
nary intervention (PCI) of CTO lesions was successful in 49% percent of
patients. The surgical success rates were only marginally better at 68%.
Currently, PCI success rates of greater than 80% are being reported in spe-
cialist Japanese, American and European Centres [4]. Despite this, referral
for PCI remains low inmany countries and the reasons are likelymultifac-
torial. Firstly, the historically poor success rates that characterised early
interventional experience continue to affect referral behaviour. While
there is a large volume of retrospective data, there is a lack of randomised
data supporting the beneﬁt of CTO revascularisation on morbidity andSW, Australia 2750.
Ireland Ltd. This is an open access artmortality. This review will focus on the development of new techniques
for CTO PCI with an emphasis on procedurally relevant histopathology
and the differing methodologies that have emerged from sites in Japan
and the United States of America. A discussion of the prognostic impor-
tance of CTOs and the rationale for revascularisation is beyond the
scope of this review and has been published elsewhere [5–27].
2. Histopathology of CTO lesions
CTOs consist of a proximal and a distal cap with an intervening
occluded segment. In one histological study the proximal cap was more
likely to be ﬁbro-calciﬁc than the distal cap. This has implications for the
particular percutaneous approach selected and explains the rationale be-
hind retrograde strategies. Despite complete occlusion on angiography,
CTOs have vascular channels that span the occluded segment [28,29].
These channels help to protect the vesselwall against theﬂow limiting ef-
fects of intimal plaque progression. There are two types of histological
vascular channels within the occluded segment of the CTO: [28,29]
1. Endothelialised microchannels (160 to 230 μm) generated via
neovascularisation that span the CTO from proximal to distal cap.
These are termed histologically recanalised segments.
2. Micro capillaries (b100 μm) that pass into small side branches or into
the vaso vasorum. The vaso vasorum is a network of vessels that arise
in adventitial layers and provide nutrients to the vessel wall. These
micro capillaries are termed non-recanalised segments, as they do
not connect the proximal and distal caps.icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to pass through the lumen of the CTO within endothelialised
microchannels and across the occlusion. Non-recanalised segments
are predisposed to subintimal wire passage. Short occlusions with a ta-
pered stumparemore likely to havehistologically recanalised segments
than longer occlusions. All CTOs with a non-tapered (ambiguous) entry
point examined histologically had non-recanalised micro capillaries
[28].
The precise composition of the intervening occluded segment is
inﬂuenced by the age of the occlusion. In younger CTO lesions there is
softer cholesterol laden material between the proximal and distal caps
that typically consists of organised thrombus, extracellular matrix,
smooth muscle cells and lipid deposits (so called loose tissue) [28,29].
This soft material contains endothelialised microchannels. Dense
ﬁbro-calciﬁc areas and micro capillary formation characterise older
occlusions. These histopathological characteristics provide
the theoretical basis for many of the CTO PCI techniques discussed later.
The CTO has traditionally been divided into “luminal” vs “subintimal
spaces”. The luminal space is deﬁned as the space containing blood
when the arterywas patent and is encircled by the intimal (endothelial)
layer. The subintimal space refers to that space external to the intimal
layer but within the vessel architecture. This includes the media
(smooth muscle) and adventitial layers. The internal elastic membrane
(IEM) surrounds the intimal layer and the external elastic membrane
(EEM) surrounds the media and is bounded by adventitia. During CTO
PCI, subintimal wire passage is within the media between the IEM
and the EEM following the path of least resistance. This theoretical
distinction is relevant when discussing the various percutaneous
techniques.
For the myocardium to remain viable in an area subtended by a CTO
there must be collateral circulation. This can occur via antegrade
bridging collaterals from the culprit vessel or retrograde collaterals from
a contralateral vessel. The ability of collateral vessels to provide sufﬁcient
ﬂow tomaintain coronary perfusion under rest and stress can be difﬁcult
to assess. Angiographic size may not predict the functionality of collat-
erals. Collateral ﬂowdistal to the CTO can further be compromised by epi-
cardial or microvascular disease in a contralateral vessel supplying
collaterals. The traditional teaching regarding the concept of “adequacy
of collateralisation” in preventing ischaemia in CTOs is now challenged
by physiological evidence. One study assessed 62 patients undergoing
CTO PCI. Sixty-one patients had physiologically signiﬁcant ischaemia
across the occlusion using FFR, irrespective of the angiographic appear-
ance of collaterals. In addition, preserved left ventricular systolic function
(present in 39 patients) did not predict adequacy of collaterals [30].2.1. Clinical and procedural considerations
Clinical indications for CTO revascularisation are the initial consider-
ation and include the severity of symptoms, level of medical therapy,
age and comorbid disease. In particular the presence of renal impairment,
cognitive impairment and medication non-concordance may inﬂuence
whether to proceed with PCI or CABG compared with medical therapy.
If an evaluation of ischaemia is required then the preferred method de-
pends upon local availability and expertise. Following informed consent,
patient preference may alter the options considered. When it has been
concluded that revascularisation with PCI is indicated, the procedure re-
quires thorough planning. Procedural success depends upon careful re-
view of the angiogram including stump morphology, length of
occlusion, calciﬁcation and presence and extent of collaterals.
Traditional factors that predict a lower PCI procedural success
rate include length of occlusion greater than (N) 20 mm, presence of
calciﬁcation within the lesion and/or artery, native vessel CTO after
CABG and the presence of bridging collaterals [31–33]. A tapered tip
occlusion is more favourable than a blunt “cut-off”, as is the absence
of side branches in close proximity to the occlusion [31–33].The J-CTO score was developed to classify lesion complexity [32]
(Fig. 1). A number of the lesion characteristics are included in the J-
CTO score, which has also been proposed as a predictor of procedural
success. This is a numerical score with higher values indicating greater
procedure complexity (Fig. 1). Its predictive capability with regard to
procedural success has been inconsistent. However, it has been shown
to correlatewith the duration required for successful intimalwire cross-
ing [32]. (Fig. 2)
An ‘ad hoc’ approach to PCI is widely discouraged to allow appropri-
ate angiographic review and informed consent. Outcomeswith PCI have
also been linked with the following factors: [34,35]
1. Operator experience [36]
2. Dual interventional cardiologist approach
3. ‘Quarantined’ laboratory time to prevent time constraints
4. Pre procedure laboratory inventory review to ensure necessary
equipment is available
5. Radiographer assistance and implementation of radiation
minimisation techniques [37,38].
In selected cases CT coronary angiography may assist in pre-
planning by providing additional morphological features of the CTO;
in particular vessel course, tortuosity and calciﬁcation [39–41].
Initiation of the procedure requires meticulous attention to arterial
access. Bilateral femoral artery access is often performed due to the
requirement for dual injection and larger guide catheters. At least 7F-
guiding catheters are suggested for CTO intervention. Anchor balloon
techniques require a 7F system. Techniques that require the use of a
microcatheter simultaneously with IVUS, or the CrossBoss dissection
system (Boston Scientiﬁc, Marlbourough, Massachusetts) require an
8F system. PCI for CTO is also feasible using radial access [42,43]. A radial
approach can be used for either the interventional or the donor guide
catheter. The availability of sheathless Eau catheters (Asahi Intecc,
Nagoya, Japan) allows a 7F and an 8F interventional lumen for device
delivery. Based upon this there is increasing frequency of a combined
femoral and radial access approach.
Simultaneous dual injection is critical for determining characteris-
tics of the CTO including lesion length, proximal and distal capmorphol-
ogy, site of side branches and extent of collaterals. Furthermore, single
catheter antegrade injection should be avoided once dissection occurs
in the antegrade spacewith subintimal entry as it may result in hydrau-
lic enlargement of the dissection plane and resulting haematoma
expansion [44].
Drug eluting stents (DES) are used almost exclusively to minimise
the risk of restenosis [45]. In the GISSOC II-GISE study, DES usage
resulted in a lower proportion of patients with recurrent ischaemia at
24 months after CTO PCI compared with bare metal stents (15.1% vs
32.1%, respectively; p = .01) [46].
3. Current PCI techniques
Recent years have seen the development of specialist operators,
techniques and equipment that have improved success rates in CTO
PCI. Since its inception, the Japanese have been at the forefront of CTO
PCI pioneering the retrograde approach. This was in part driven
by historically low rates of CABG and therefore the necessity to progress
alternative treatments. Adaptations to the Japanese approach
have more recently been published from high volume operators in the
United States with similarly high rates of success. Bothmethods require
the pre-procedural planning and set-up speciﬁed above.3.1. The Japanese methodology [44,47]
Japanese CTO specialists have propagated the traditional approach
to CTO PCI. This technique usually begins with an antegrade (proximal
Fig. 1. The J-CTO score is used to characterise lesion complexity in a standardised way. Reproduced with permission from Morino et al. [32].
Fig. 2. The J-CTO score predicts the ability to cross the lesion antegrade in less than 30min.
This underpins the algorithmand rapid shifts in strategy advocated in the hybrid approach
(see below) Reproduced with permission fromMorino et al. [32].
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CTO antegrade. These include:
1. Single wire manipulation with wire escalation.
2. Parallel wiring.
3. Seesaw wiring.
4. Balloon anchoring.
5. IVUS guided wiring.
The aim is for a luminal cross of the occluded segment and a signif-
icant amount of time may be spent in achieving this. If the subintimal
space is entered, the Japanese emphasise limiting the distance of
antegrade dissection by attempting to re-enter quickly or switching to
a retrograde strategy.
Table 1
An overview of currently available wires used in CTO.
Wire Manufacturer Design/Lengths Coating Tip load
(g)
Penetration force kg/in.2
Fielder FC Asahi Non-tapered tip. 0.014 in., 180
and 300 cm lengths.
Hydrophilic, polymer jacket 0.8 N/A
Fielder XT Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 and 300 cm lengths
Hydrophilic, polymer jacket 0.8 N/A
Fielder XT — A
(A for antegrade)
Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 and 300 cm lengths
Hydrophilic, polymer jacket 1.0 N/A
Fielder XT — R
(R for retrograde collateral cross)
Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 and 300 cm lengths
Hydrophilic, polymer jacket 0.6 N/A
Pilot 50 Abbott Non-tapered tip. 0.014 in., 190
and 300 cm lengths
Hydrophilic, polymer jacket 1.5 N/A
Sion
For retrograde collateral cross
Asahi Non-Tapered tip. 0.014 in., 180
and 300 cm lengths
Hydrophilic, non-jacketed over
spring coil and tip.
0.7 N/A
Sion Blue
Workhorse wire for procedure
completion
Asahi Non-Tapered tip. 0.014 in., 180
and 300 cm lengths
Hydrophilic, non-jacketed over
spring coil. Hydrophobic tip.
0.5 N/A
Gaia First Asahi Tapered tip 0.010 in. Shaft 0.014
in., 190 cm
Hydrophilic, non-jacketed. Tip
hydrophilic
1.5 Penetration efﬁciency
rather than power. On
par with miracle 6
Gaia Second Asahi Tapered tip 0.011 in. Shaft 0.014
in., 190 cm
Hydrophilic, non-jacketed. Tip
hydrophilic
3.5 Penetration efﬁciency
rather than power. On
par with miracle 12
Gaia Third Asahi Tapered tip 0.011 in. Shaft 0.014
in., 190 cm
Hydrophilic, non-jacketed.
Tip hydrophilic
4.5 Penetration efﬁciency
rather than power. On
par with Conquest Pro 12
Miracle 3/MIRACLEbros 3 Asahi Non-tapered tip. 0.014 in., 180 cm
length
Hydrophobic (silicone) 3.0 20
Miracle 4.5/MIRACLEbros 4.5 Asahi Non-tapered tip. 0.014 in., 180 cm
length
Hydrophobic (silicone) 4.5 30
Miracle 6/MIRACLEbros 6 Asahi Non-tapered tip. 0.014 in., 180 cm
length
Hydrophobic (silicone) 6.0 39
Miracle 12/MIRACLEbros 12 Asahi Non-tapered tip. 0.014 in., 180 cm
length
Hydrophobic (silicone) 12.0 78
Ultimate Bros 3 Asahi Non-tapered tip. 0.014 in., 180 and
300 cm lengths
Hydrophilic, non-jacketed 3 20
Pilot 150 Abbott Non-tapered tip. 0.014 in., 190 and
300 cm length
Hydrophilic, polymer jacketed 2.7 N/A
Pilot 200 Abbott Non-tapered tip. 0.014 in., 190 and
300 cm length
Hydrophilic, polymer jacketed 4.1 N/A
Conquest/Conﬁanza Asahi Tapered tip 0.009 in. Shaft 0.014
in. 180 cm length. Spring coil
length 20 cm
Hydrophobic (silicone) 9.0 142
Conquest Pro/Conﬁanza Pro Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 cm length. Spring coil
length 20 cm
Hydrophilic non-jacketed over spring
coil. Hydrophobic tip and shaft
9.0 142
Conquest Pro 12/Conﬁanza Pro 12 Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 cm length. Spring coil
length 20 cm
Hydrophilic non-jacketed over spring
coil. Hydrophobic tip and shaft
12.0 189
Conquest Pro 8-20/Conﬁanza
Pro 8–20
Asahi Tapered tip 0.009 in. Shaft 0.014
in., 180 cm length. Spring coil
length 17 cm
Hydrophilic non-jacketed over spring
coil. Hydrophobic tip and shaft
20.0 315
High Torque CROSS IT 100 XT Abbott Tapered tip 0.010 in. Shaft 0.014
in. 190 and 300 cm length.
Hydrophilic including tip, non-jacketed 1.7 22
High Torque CROSS IT 200 XT Abbott Tapered tip 0.010 in. Shaft 0.014
in. 190 and 300 cm length.
Hydrophilic including tip, non-jacketed 4.7 60
High Torque CROSS IT 300 XT Abbott Tapered tip 0.010 in. Shaft 0.014
in. 190 and 300 cm length.
Hydrophilic including tip, non-jacketed 6.2 79
High Torque CROSS IT 400 XT Abbott Tapered tip 0.010 in. Shaft 0.014
in. 190 and 300 cm length.
Hydrophilic including tip, non-jacketed 8.7 110
High Torque Progress 40 Abbott Non-Tapered tip 0.014 in. 190 and
300 cm length.
Hydrophilic, non-jacketed. 4.8 30
High Torque Progress 80 Abbott Non-Tapered tip 0.014 in. 190 and
300 cm length.
Hydrophilic, non-jacketed. 9.7 63
High Torque Progress 120 Abbott Non-Tapered tip 0.014 in. 190 and
300 cm length.
Hydrophilic, non-jacketed. 13.9 90
High Torque Progress 140T Abbott Tapered tip 0.0105 in. Shaft
0.014 in. 190 and 300 cm length.
Hydrophilic, non-jacketed. 12.5 144
High Torque Progress 200T Abbott Tapered tip 0.009 in. Shaft 0.014
in. 190 and 300 cm length.
Hydrophilic, non-jacketed. 13.3 209
Galeo Hydro S BIOTRONIK Non-tapered tip. 0.014 in. 175 cm
length.
Hydrophilic 12 cm including tip.
Hydrophobic shaft. Non-jacketed
3.1 N/A
Galeo Hydro F BIOTRONIK Non-tapered tip. 0.014 in. 175 cm
length.
Hydrophilic 12 cm including tip.
Hydrophobic shaft. Non-jacketed
6 N/A
Galeo Hydro M BIOTRONIK Non-tapered tip. 0.014 in. 175 cm Hydrophilic 12 cm including tip. 4.5 N/A
(continued on next page)
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Table 1 (continued)
Wire Manufacturer Design/Lengths Coating Tip load
(g)
Penetration force kg/in.2
length. Hydrophobic shaft. Non-jacketed
PT Graphix Boston Non-Tapered tip. 0.014 in.. 182
and 300 cm lengths
Hydrophilic, non-jacketed. 4.0 26
Shinobi CORDIS Non-tapered tip. 0.014 in. 180
and 300 cm lengths
Hydrophillic. Teﬂon coated. 2.0 13
Shinobi Plus CORDIS Non-tapered tip. 0.014 in. 180
and 300 cm lengths
Hydrophilic Teﬂon coated. 4.0 26
Persuader 3 MEDTRONIC Non-tapered tip. 0.014 in. 190
and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
5.1 33
Persuader 6 MEDTRONIC Non-tapered tip. 0.014 in. 190
and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
8 52
Persuader 9 MEDTRONIC Tapered tip. 0.010 in., Shaft
0.014 in. 190 and 300 cm
lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
9.1 96
Provia 3 MEDTRONIC Non-tapered tip. 0.014 in.
180 and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
3 19
Provia 6 MEDTRONIC Non-tapered tip. 0.014 in.
180 and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
6 39
Provia 9 MEDTRONIC Tapered tip. 0.009 in., Shaft
0.014 in. 190 and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
9 142
Provia 12 MEDTRONIC Tapered tip. 0.009 in., Shaft
0.014 in. 190 and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
12 189
Provia 15 MEDTRONIC Tapered tip. 0.009 in., Shaft
0.014 in. 190 and 300 cm lengths.
Available in hydrophilic (non-jacketed)
and hydrophobic forms. Tip
hydrophobic in all variants
15 236
Muskie Vascular
Solutions, Inc.
Non-Tapered tip. 0.014 in. 195
and 300 cm lengths.
Hydrophillic, non-jacketed 3 20
Muskie Vascular Solutions, Inc Non-tapered tip. 0.014 in. 195
and 300 cm lengths.
Hydrophillic, non-jacketed 4.5 30
Muskie Vascular Solutions, Inc Non-tapered tip. 0.014 in. 195
and 300 cm lengths.
Hydrophillic, non-jacketed 6 39
Muskie Vascular Solutions, Inc Non-tapered tip. 0.014 in. 195
and 300 cm lengths.
Hydrophillic, non-jacketed 9 58
Muskie Vascular Solutions,
Inc
Non-tapered tip. 0.014 in. 195
and 300 cm lengths.
Hydrophillic, non-jacketed 12 78
High Torque ﬂoppy extra support Abbott Soft tip, high shaft support Hydrophobic 0.6 N/A
Grand slam Asahi Soft tip, high shaft support Hydrophobic 0.7 N/A
Stabiliser CORDIS Soft tip, high shaft support Hydrophobic Very soft tip N/A
Stabiliser Plus CORDIS Soft tip, very high shaft support Hydrophobic Very soft tip N/A
RG 3 Asahi Non-tapered tip. Tip 0.014 in.,
Shaft 0.010 in. 330 cm length
Hydrophilic, non-jacketed over the
shaft
3.0 N/A
Rotawire Boston Scientiﬁc Monoﬁlament wire. Tip 0.014 in.
Shaft 0.009 in. 325 cm
Hydrophobic N/A N/A
ViperWire Advance Cardiovascular
systems
Non-tapered tip. 0.014 in. 330 cm Hydrophobic N/A N/A
N.B. Penetration power is the tip load or tip stiffness (in kg) divided by the area of the wire tip (square inches). It is a better representation of wire penetration ability. Shaft stiffness is a
different measure that assesses delivery of equipment along the wire shaft. Penetration efﬁciency is a new concept in relation to the Gaia wire (Asahi Intecc), which describes the coex-
istence of high penetration force with maintained steerability and torque response within the CTO segment. Tip load and tip diameter data obtained from the respective manufacturer.
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3.1.1.1. Single wire manipulation with wire escalation. Initially a soft
hydrophilic wire (e.g. Fielder XT-A, Asahi Intecc) is chosen with the
aim of seeking out microchannels to traverse the CTO in the intimal
space (soft probing). Non-hydrophilic wires with increasing penetra-
tion force are used as needed in ﬁbrous CTO segments for loose tissue
tracking or intimal plaque tracking [47]. Gradual escalation of wire tip
load aims to traverse the CTO with the safest wire, reducing the chance
of perforation — the “wire escalation strategy” [47]. Increasingly, the
Japanese are using the Gaia wire (Asahi Intecc) during wire escalation.
This is a novel CTO wire utilising composite core technology that
theoretically allows greater directional control within the body of
the CTO without compromising penetration power. Consequently,
manipulation via redirection and penetration is required. They have
begun to incorporate this wire early during wire escalation for loosetissue and intimal plaque tracking, as well as retrograde distal cap
penetration. Protocol based wire escalation cannot be compiled due to
variability among Japanese operators.
An overview of available CTO wires is shown above (Table 1). Higher
tip load/penetration force wires (particularly if hydrophilic or polymer
jacketed e.g. Pilot 200, Abbott) increase the chance of subintimal
tracking or passage outside of the vessel architecture. Traditional high
penetration force CTO wires (e.g. Conquest Pro, Asahi Intecc) are hydro-
phobic at the tip and are difﬁcult to redirect, with an associated risk of
perforation in tortuous vessels and over long segments.
Wire escalation is performed with an over the wire (OTW)
microcatheter (Table 2). OTW balloons are rarely used, as they induce
wire bias and have a proﬁle that may make it difﬁcult to cross the
occluded segment after successful wiring.
The microcatheter offers several advantages. Firstly it provides added
support to the wire and increases penetration force. Secondly it allows
Fig. 3. Controlled drilling vs penetration for intimal plaque tracking.
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wire reshaping. The Corsair catheter (Asahi Intecc) is an OTW hybrid
catheter that has features of a microcatheter and a support catheter
[48]. It has become the initial microcatheter of choice for most CTO inter-
ventions and is usually able to traverse occluded segments once wiring
has occurred.
Microchannel navigation and loose tissue tracking utilise the
traditional wire manipulation techniques used in conventional
angioplasty. Intimal plaque tracking requires two CTO speciﬁc wire tech-
niques during wire escalation [47]. Firstly controlled drilling, where the
wire is spun through 360-degree rotations and very gently advanced for-
ward such that the wire seeks its own path through the CTO (Fig. 3).
Secondly, penetration involves pushing the wire with gentle rotation
for penetration of calciﬁed or ﬁbrotic CTO segments. This is also useful
for focused reentry to the true lumen from the subintimal space. The
wire technique and shape required for these techniques are shown
below (Figs. 4 and 5).
3.1.1.2. Parallel and seesawwiring technique. In the parallel wire strategy,
awire that enters the subintimal space is left in position to seal that tract
and act as a marker. Continued advancement of this wire close to the
distal cap should be avoided as it can collapse the distal true lumen
and make reentry difﬁcult. A second penetrating wire is therefore
introduced using a microcatheter and attempt made at redirection
into the true lumen (Fig. 6). The Crusade Catheter (Kaneka, Osaka,
Japan) is a double lumen microcatheter that contains both a monorail
and an OTW port. It is ideally suited to parallel wiring by allowing the
introduction of multiple wires without removal of the catheter from
an optimal position.
Seesaw wiring (Fig. 7) involves the use of two microcatheters and
wires. It has the advantage of avoiding the need for complex exchange
of OTW microcatheters. Also wires can be reshaped and their roles
switched promptly.
3.1.1.3. Anchor wire or anchor balloon technique. This involves placing a
second support wire in a side branch proximal to the occlusion to
increase support from the guiding catheter. The balloon anchoring
technique involves inﬂating an appropriately sized balloon in the
side branch to stabilise the guide and increase guide support. TheTable 2
Overview of available microcatheters (data from manufacturer).
Microcatheter Length Material Size
Corsair 135 cm
(antegrade)
150 cm
(retrograde)
10 wires of tungsten
braiding to form a metallic
tube.
Tapered soft tip
and hydrophilic polymer
coating
1.3F
distal
2.8F prox
Tornus
Tornus 88 Flex
135 cm
135 cm
0.12 mm × 8
wires
0.18 mm × 8
wires
Intertwined wires make
up the shaft
2.1F prox
1.8F dista
3.0F prox
to 2.1F di
Stride 105 cm,
125 cm,
130 cm
Stainless steel braiding 2.2 and 2
versions
Fine cross 135 cm
150 cm
Hydrophilic coating 1.8F dista
2.6F prox
Venture
OTW and monorail
versions
140 cm
OTW
145 cm
monorail
Deﬂectable catheter up to 90° 1.24 mm
0.56 mm
Crusade 140 cm 2.2F dista
diameterdisadvantages with these methods include the risk of injury to the
side branch and ischaemia if the side branch supplies a largemyocardial
territory.
3.1.1.4. Intravascular ultrasound guided wiring technique. Intravascular
ultrasound (IVUS) features heavily in the Japanese strategy.
IVUSguidedproximal cappenetrationmaybeusedwhenanocclusion
may be ﬂush with a large side branch. An IVUS catheter can be placed in
the proximal side branch for interrogation of the CTO lesion in the main
lumen (Fig. 8). IVUS investigation also helps to examine the composition
of the plaque and its consistency at the entry site.
If thewire enters a false lumen after the distal cap, the IVUS can be ad-
vanced over this wire to investigate the distal true lumen and to assess a
favourable reentry location (Fig. 9).
3.1.2. Retrograde approach
Japanese CTO operators pioneered the retrograde CTO approach [44,
47,50]. The retrograde approach refers to CTO access of the distal cap
via collateral vessels. It is usually reserved as a second line strategy for
failed intimal antegrade crossing. Failure occurs where the antegrade
wire fails to make forward intimal progress or enters the subintimal
space and prompt reentry to the true lumen is not possible. The overall
aim is to connect antegrade and retrograde channels to allow successfulComments Maker
imal
Tapered tip allows progress through occluded
segment.
Caution in calciﬁed segments as over-rotation
may lead to entrapment and unravelling.
Mainstay device in CTO intervention.
Asahi
imal
l
imal
stal
Corkscrew motion to forward advance
Advance (counterclockwise rotation)
Withdraw (clockwise rotation)
After 20 turns of rotation open haemostatic valve
to released kinetic energy. Always rotate
clockwise to exit lesion.
Tornus 88 Flex has twice the penetration ability
Asahi
.6F Soft tip. Unlikely to traverse the CTO segment.
Reduced wire bias compared to OTW balloon.
Asahi
l
imal
May allow passage due to small distal diameter.
Highly deliverable.
Terumo
proximal
distal
Steerable catheter for wiring tortuous and
angulated branches
Vascular Solutions
Inc
l Double lumen with monorail and OTW
component. Ideal for parallel wiring and
bifurcation strategies
Kaneka
Fig. 4. A 30 to 60 degree distal bend 1 to 2 mm from the tip should be placed on the wire
for controlled drilling or penetration. Reentry into the true lumen requires a high penetra-
tion force wire with a more acute bend. Reproduced with permission from Thach N et al.
Practical Handbook of Advanced Interventional Cardiology: Tips and Tricks, 4th Edition
Wiley and Sons [49].
Fig. 6. Parallel wire technique.
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proximal or distal cap of the CTO within normal vessel is ideal.
The retrograde approach requires the presence of useable collaterals
from the opposing circulation and allows access to the CTO, via the softer
distal cap. Angiographic collaterals can be divided into septal and epicar-
dial channels which have different characteristics. Septal channels are
safer for wire crossing, as they are less prone to rupture. Successful cross-
ing is not always predictable based on angiographic appearance. In addi-
tion, small side branches and tortuosity are often underappreciated on
angiography. The Japanese advocate careful progress with repeat injec-
tions through the microcatheter to conﬁrm position in the correct chan-
nel. If perforation occurs, bleeding is normally contained and rarely
results in catastrophic outcomes. Epicardial collaterals on the other
hand are fragile and associated with high mortality if rupture occurs
and is untreated (usually via cardiac tamponade).Fig. 5. Secondary bend 3 to 6 mm from the tip is useful if the proximal vessel is tortuous.In contrast to the antegrade strategy, subintimal tracking is not
considered a failure as it facilitates procedural success using various strat-
egies such as the reverse CART manoeuvre (see below).
The retrograde wire escalation strategy is initially used with a
microcatheter to cross the body of the CTO. If the CTO is crossed
in the intimal space, the wire is then externalised and angioplasty
commences — termed retrograde wire cross. IVUS may be used over the
antegradewire to conﬁrm that the retrogradewire is luminal prior to ad-
vancement through the proximal vessel.
Failure of luminal retrograde wire cross (either subintimal wire
passage or failure to advance the wire within intima) increases
procedural complexity. The Japanese will then introduce an antegrade
wire (if not already present)— this is termed antegrade preparation. Sub-
sequently, there are four possible fates for the antegrade and retrograde
wires that require different strategies for successful retrograde CTO cross-
ing. The possibilities are listed below (Table 3).
Firstly both antegrade and retrogradewires are in the intimal space. In
this case the objective is either to advance the antegrade or retrograde
wire with the opposing wire as a landmark toward the opposing chan-
nel — so called “kissing wire cross”. Antegrade balloon dilatation is the
next strategy. This expands the antegrade channel to increase the chance
of the retrogradewireﬁnding the antegrade channel and advancing in the
intima toward the antegrade guiding catheter. If this fails, intentionally
penetrating the subintimal space with the antegrade wire followed by
balloon inﬂation may increase success in connecting the channels.
The most favourable scenario is that both antegrade and retrograde
wires are in the subintimal space. The two sides are usually connected
when the antegrade space is enlarged via balloon dilatation. This is
known as reverse controlled antegrade and retrograde subintimal-
tracking (reverse CART) manoeuver (Fig. 10).
The most challenging scenario occurs where the retrograde wire is
subintimal and the antegrade wire is in the true lumen. The difﬁculty
arises because of a large layer of tissue between the two wires. InﬂationFig. 7. Seesaw wiring technique.
Fig. 8. Flush occlusion with a side branch. Entry into the CTO from the side branch can be
facilitated with IVUS placed in the side branch.
Table 3
An overview of connecting antegrade and retrograde channels for successful retrograde
cross.
Wire position Strategy
Antegrade intimal
Retrograde intimal
1. Kissing wire technique.
2. Dilatation antegrade
3. Purposeful subintimal-tracking antegrade or retrograde
Antegrade subintimal
Retrograde subintimal
(Ideal situation)
1. Reverse controlled antegrade and retrograde subintimal
tracking
(Reverse CART) using an adequately size antegrade
balloon
Antegrade intimal
Retrograde subintimal
(least favourable)
1. Aggressive antegrade dilatation to disrupt the body
of CTO and open a passage
Antegrade subintimal
Retrograde intimal
1. Purposeful subintimal passage then advance knuckle
retrograde and connect spaces via reverse CART.
2. CART procedure as second line with caution.
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the body of the CTO and open a passage into the subintimal space. This
will allow the retrograde wire to engage the newly created space and
hence the antegrade true lumen.
Finally the retrograde wire is intimal and the antegrade wire is
subintimal. A CART procedure has been advocated to deal with this
scenario. This involves dilating the tract retrograde — the opposite of
the reverse CART. The routine use of the CART procedure in this scenario
should be avoided, as there is inherent risk in delivering bulky devices
along fragile collaterals. Advancing the wire retrograde until it reaches
an adjacent subintimal space as the antegrade wire and ﬁnishing with a
reverse CART to connect the spaces is a more efﬁcient and safe method.
3.1.3. Equipment and wire management following successful CTO crossing
A number of procedural issues require speciﬁc attention once the
spaces are united:
1. After retrograde crossing and during PCI, the retrogrademicrocatheter
should remain in the distal portion of the native artery covering the
collateral bed. Removal prior to PCI completion may result in wire in-
duced collateral transection with resulting rupture.
2. After retrograde luminal connection the wire should be externalised
(retrieved out the contralateral sheath). This is performed via wiring
of the antegrade guiding catheter or by snaring and retrieving the
wire. The retrograde wire used to cross the occlusion is too short for
externalisation and is replaced with a long 300 to 325 cm wire.
3. Inability to perform balloon dilatation is an important problem
particularly in highly calciﬁed vessels. While rotational atherectomy
through a dissection plane is generally contraindicated, the Japanese
are conﬁdent in using this modality with small to medium burr sizing
and in the absence of angiographic staining. If signiﬁcant stainingFig. 9. IVUS placed in the subintimal space can help guide reentry to the true lumen.precludes rotational atherectomy, the procedure may need to be
aborted to allow healing and the procedure rescheduled.
4. Removal of OTWequipmentwhilemaintaining distalwire position, or
exchanging high tip load wires for softer workhorse wires can be
achieved via three methods: doc wire, balloon trapping and the
aqua plane technique. Regardless of the method used, reliable
maintenance of distal wire position is pivotal to procedural success.
3.1.4. Limitations of disseminating the Japanese approach
There are barriers limiting dissemination of some aspects of the
Japanese technique to other countries. Firstly the success of Japanese
CTO specialists likely reﬂects a high case volume that allows development
of superior wire technique and skill. Unique to Japan is the situation
where patient preference results in low rates of CABG and this results in
preferential treatment with PCI. Second, health systems outside of Japan
may have greater ﬁnancial and laboratory time limitations. Long case du-
ration may not be feasible when laboratory time is limited. Finally, the
Japanese approach is highly individualised making it difﬁcult to teach
and disseminate. Concerns have been raised over radiation and contrast
volume during protracted cases.
3.1.5. The American methodology [34,35,49,50]
In response to these limitations, the North American total occlusion
group has developed an alternate strategy to CTO PCI — the “hybrid”
approach. The stated aims of this strategy are to create a systematic
approach to CTO intervention with the following goals:
1. Maximise success, while minimising radiation dose, contrast and
procedural time.
2. Enhance the teaching and dissemination of CTO techniques and to
reduce interoperator variability in CTO success rates via an algorith-
mic approach.
3. Focus on usingworkhorse equipment available inmost intervention-
al laboratories. Hence a small number of wires are suggested for
routine inventory. It proposes easier integration into busy catheter
laboratories with minimal interruption to work ﬂow.
4. Clinical factors decide whether revascularisation is needed and
precise dual injection angiography to delineate anatomy deﬁnes
the appropriate technique.
Deﬁnite time limits are set for a given strategy with a rapid shift to an
alternate approach if no headway ismade at the speciﬁed time limit. Lim-
itations are set on contrast volume and radiation dose and the procedure
is aborted if unsuccessful despitemultiple strategies. Failure does not pre-
clude repeat intervention.
The proposed methodology is shown below (Fig. 11).
The approach is dictated by 4 major anatomical factors — proximal
cap anatomy, length of occlusion, the presence of a landing zone in
Fig. 10.Reverse CART technique. A. Angiographic depiction of the technique. B. A balloon is
inﬂated over the antegradewirewithin the subintimal (subluminal) space that is connect-
ed proximally to the true lumen. The retrograde wire is advanced toward the newly
created space. Imaged reproduced with permission from Joyal et al. [50].
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erals. As with the Japanese approach, procedural preparation is critical
to success.
3.1.6. Antegrade approach
The antegrade approach requires deﬁned proximal cap anatomy
ideally with a tapered stump or deﬁned entry point. The antegrade
approach is technically demanding when the entry point is ambiguous
or at a bifurcation.
3.1.6.1. Short lesion (b20 mm). The approach for short lesions is similar
to the Japanese strategy. Wire escalation is chosen as the initial modal-
ity, as a successful luminal cross ismore likelywith short occlusions. The
major differences are that speciﬁed time limits are set for a change in
strategy if successful crossing is not achieved. Also, the technique
proposes the use of only a few workhorse wires (likely present in
most interventional labs) with rapid wire escalation to wires with a
very high tip load if the lesion is not crossed. Intermediate tip load(3.0 to 6.0 g) wires are not present in this algorithm as these wires are
felt to be more likely to enter the subintimal space. This is known as
the “stiffer is safer” principle [34,35].
CTO crossing is initially attemptedwith a soft tipped polymer jacketed
wire to seek out microchannels — “probing” (e.g. Fielder FC/XT, Sion
[Asahi Intecc], Pilot 50 [Abbott Vascular, Abbott Park, Illinois]). If this
fails the next step is rapid escalation to stiffer wires such as the
Conquest Pro 12 (Asahi Intecc) if there is a clear distal target. The Pilot
200 (Abbott Vascular) is suggested if the path is unclear or the vessel
is tortuous.
Passage into the subintimal space requires an adaptation in strategy.
The goal now shifts to traversing the CTO in the subintimal space utilising
the safest possible method that minimises the risk of perforation. The al-
gorithm advocates the use of a dedicated dissection/reentry device— the
CrossBoss/Stingray reentry system (Boston Scientiﬁc). The CrossBoss
(Fig. 12) [34,35,51] is a metal OTWmicrocatheter with a rounded tip to
minimise the risk of perforation compared with advancing high tip load
wires. It is designed to traverse the occluded segment through the
subintimal space until it is adjacent to normal true lumen where reentry
can occur. This device is rotated rapidly in either direction and advanced
without a wire.
The Stingray device (Fig. 13) is then proposed to facilitate reentry to
the true lumen [34,35,51]. It consists of a balloon that assumes a ﬂat
shape when inﬂated and allows orientation of the wire toward the
adjacent true lumen. The balloon has 2 exit ports opposite one another
with a radio-opaque marker distal to each port for orientation toward
the true lumen. It includes a high penetration force wire with an
extreme tapered distal tip (Stingray wire, Boston Scientiﬁc). The
Stingraywire is advanced through the exit port into the true lumen to cre-
ate a communicating channel with the subintimal space. It is then
removed and a Pilot 200 used to ﬁnd this newly created channel for
entry into the true lumen and distal wire passage. The wire is then
exchanged for a workhorsewire and stenting is performed distal to prox-
imal in the routine fashion. In the absence of usable retrograde channels,
inability to re-enter the true lumen antegrade represents a procedural
failure and the procedure is terminated.
3.1.6.2. Long lesions (N20 mm). The algorithm suggests subintimal
tracking as an initial strategy for long segment (N20 mm) lesions. The
rationale is that for long lesions, intimal crossing is unlikely even in
the hands of expert operators [32]. Early use of the CrossBoss/Stingray
system is advocated to reduce procedural duration.
If antegrade dissection/reentry fails, retrograde bailout via the reverse
CART strategy is recommended if useable collaterals exist.
3.1.7. Retrograde approach
The retrograde approach is proposed as a ﬁrst line strategy where the
proximal stump is ambiguous. Wire escalation retrograde through the
distal cap is reserved for short lesions (b20 mm). If the lesion is crossed
into the proximal true lumen the wire can then be externalised.
Purposeful dissection retrograde from the outset is reserved for long
lesions (N20 mm). The knuckle wire technique is used as the dissection
strategy of choice (Fig. 14). It has little risk of perforation due to the lack
of wire tip contact with the subintimal space — hence it is more likely
to remain in the vessel architecture. To perform this technique the stiff
wire is removed and replaced with a broadly curved softer jacketed
wire that is pushed (never rotated) and advanced through the subintimal
space. A wire is then advanced from the antegrade direction and the
spaces connected via the reverse CART as occurs with the Japanese
strategy.
3.1.8. Controversies of the North American approach
There are limitations with this strategy. A possible disadvantage with
this approach is that purposeful subintimal tracking with a knuckle wire
or CrossBossmaymake it difﬁcult to salvage large side branches.Many fa-
vour exhausting all attempts at true lumen cross when large side
Fig. 11. The American methodology— “hybrid approach”. Anatomy deﬁnes the strategy [34,35]. A minimal number of wire choices are available to simplify methodology, minimise cost
and allow adoption of the technique in a variety of catheter laboratory environments.
Fig. 12. CrossBoss dissection system (Boston Scientiﬁc) [51]. Fig. 13. The Stingray reentry system (Boston Scientiﬁc) [51].
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Fig. 14. A knuckle is formed on the retrograde wire by ﬁrst fashioning a broad curve and
then advancing forward. A soft polymer jacketed wire (e.g. Fielder XT, Pilot 50) is ideal.
Image reproduced with permission from Joyal et al. [50].
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method (such as the Stingray balloon), or retrograde bailout (absence of
usable collaterals or expertise), the procedure will terminate with
subintimal wire passage if wire reentry is not possible. Purposeful dissec-
tion strategies increase the risk of haematoma formation in the subintimal
space. Uncontrolled haematomamay rapidly compress the true lumen to
the point where reentry is impossible. Haematoma management strate-
gies include controlling knuckle size and the STRAW technique [34,35].The importance of minimising the distance of subintimal tracking is
uncertain. The approach of creating long segments of antegrade
dissection followed by reentry (the STAR technique) has been associated
with signiﬁcant restenosis in long term follow-up and is not widely prac-
ticed [52]. Subintimal tracking with the CrossBoss and Stingray system
mimics the STAR technique inprinciple. Long term stent patency and clin-
ical outcomes associatedwith stenting across large false channels created
by these devices has not been assessed in controlled trials. In particular,
the effects on stent endothelialisation, late acquired stent malapposition
and duration of dual antiplatelet therapy are uncertain.
4. Management of complications
The risk of coronary perforation from the antegrade and retrograde
approach was 0.4% in the J-CTO registry [32]. Management includes
prolonged balloon inﬂation and covered stent implantation. Reversal of
anticoagulation should be performed judiciously to prevent guide throm-
bosis. Pericardiocentesis is occasionally required and should be consid-
ered when rapid haemodynamic compromise occurs.
Collateral channel rupture is potentially fatal. Septal collateral rupture
usually results in self-limiting septal haematoma and may be managed
conservatively. Epicardial collateral rupture is more serious and often re-
quires pericardial drainage followed by antegrade and retrograde coiling
to complete haemostasis. Coils should be available and operators should
be familiar with their use. Reversal of anticoagulation may be life saving
but carries a risk of guide thrombosis, that may compromise non-
occluded vessels.
Guide thrombosis is a potential complication during prolonged
procedures. Regular activated clotting time (ACT) checks should be
performed with a target ACT of N300 s.
Contrast volume is closelymonitored and should beminimised at all
times.
Routine radiation minimisation techniques are particularly important
with prolonged procedures. This involves monitoring patient skin dose,
reducing ﬂuoroscopy frame rates and angulation change of the image in-
tensiﬁer at regular intervals to prevent intensiﬁed skin doses.
Intraprocedural blood loss should be minimised by careful attention to
Y-adapter haemostasis.
Over treatment of distal disease should be avoided. Chronic under ﬁll-
ingmakes it difﬁcult to assess true vessel size.With time, vasodilation and
remodelling may result in signiﬁcant improvements.
5. Conclusion
CTOs are a common and prognostically important ﬁnding during cor-
onary angiography. Percutaneous intervention of chronic occlusions
pioneered by the Japanese and adapted by North American operators
nowoffers a feasiblemanagement strategy for patients.Withmentorship,
patient selection and specialised equipment PCI success rates
are improving worldwide. While the Japanese and North American strat-
egies appear divergent, both add considerable expertise to CTO strategies.
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